Alopecia Areata Center for Research Translation (AACORT)

斑秃研究翻译中心 (AACORT)

• 批准号: 10091972
• 负责人: Angela M Christiano
• 金额: $ 155.48万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-16 至 2023-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10091972
• 关键词: Academic Medical Centers; Affect; Alopecia Areata; Antigens; Autoimmune Diseases; Clinical; Clinical Trials; Consultations; Core Facility; Correlative Study; Data Analyses; Databases; Development; Disease; Evaluation; Evidence based treatment; Faculty; Fostering; Genetic; Genomics; Goals; In Vitro; Individual; Infrastructure; Innovative Therapy; Institution; Link; Mission; Natural Immunity; Office of Administrative Management; Pathogenesis; Patients; Pharmaceutical Preparations; Proteomics; Research; Research Design; Research Personnel; Research Project Grants; Resources; Safety; Series; Services; Talents; Testing; Translational Research; Work; acquired immunity; administrative database; clinical development; cohort; design; experience; in vivo; inhibitor/antagonist; innovation; microbiome; novel therapeutic intervention; novel therapeutics; pre-clinical; preclinical study; programs; transcriptomics; translational pipeline; translational study

Overall AACORT Abstract The Alopecia Areata Center of Research Translation (AACORT) at Columbia University Medical Center (CUMC) is focused on the singular goal of developing new treatments for alopecia areata (AA). The mission of the AACORT is to leverage our recent discoveries beginning to unravel the genetic basis of AA and the fact that its pathogenesis is linked to dysregulation of both innate and acquired immunity, and to synergize these findings into translational studies that will lead to novel therapies for this disease, including the repurposing of existing drugs. In the past few years, the AACORT team has made transformative progress in understanding the genetic basis of AA, as well as initiating a series of clinical trials employing mechanism-driven targeted JAK inhibitors aimed at reversing the disease. While this class of drugs is having a profound impact on guiding clinical development efforts in AA, there is much more work to be done, since clearly many patients do not respond to these drugs. The goal of this AACORT is to build upon our established translational pipeline to leverage our basic and preclinical discoveries into the clinical setting. This AACORT is centered around a central Research Project that focuses on the Translational Science of Alopecia Areata, and deals with innovative translational aspects of the disease, including initiating factors such as the microbiome; preclinical studies focused on antigen discovery and testing new therapeutic approaches in vitro and in vivo; and clinical correlative studies designed to rigorously assess the efficacy and safety of new drugs coming available for patients with AA. The Research Project is supported by the Translational and Clinical Resource Core (TRAC), and the Data Analysis and Translational Applications (DATA) Core, which bring together an outstanding cadre of talented, committed and scientifically diverse faculty from across the institution. The AACORT is supported by a highly capable and experienced Administrative Core that provides its vitally important organizational infrastructure. The goal of the AACORT is to surmount barriers to translational application of basic discoveries that have the potential to revolutionize the management of this heretofore intractable and debilitating disorder.

总体上摘要 哥伦比亚大学医学中心的脱发研究翻译中心（AACORT） （CUMC）专注于为脱发Areata（AA）开发新疗法的单一目标。任务 AACORT是利用我们最近的发现开始揭示AA的遗传基础和事实 它的发病机理与先天和获得免疫的失调有关，并协同这些 转化研究的发现将导致这种疾病的新疗法，包括重新利用 现有药物。在过去的几年中，Aacort团队在理解方面取得了变革性的进步 AA的遗传基础，以及采用机构驱动的靶向JAK的一系列临床试验 旨在逆转疾病的抑制剂。虽然这类毒品对指导产生了深远的影响 AA的临床开发工作，还有更多的工作要做，因为显然许多患者没有 回应这些药物。这个AACort的目的是建立在我们既定的翻译管道上 利用我们的基本和临床前发现进入临床环境。这个aacort以一个为中心 中央研究项目的重点是Areata的脱发科学，并处理 疾病的创新翻译方面，包括引发微生物组等因素；临床前 研究重点是抗原发现和测试体外和体内的新治疗方法。和临床 相关研究旨在严格评估可用于的新药的功效和安全性 患有AA的患者。研究项目得到了转化和临床资源核心（TRAC）的支持， 以及数据分析和翻译应用程序（数据）核心，它们将出色的干部汇集在一起 来自整个机构的才华横溢，承诺和科学多元化的教师。支持AACORT 由高度和经验丰富的行政核心提供的，它提供了至关重要的组织 基础设施。 AACORT的目的是克服基本发现的翻译应用障碍 这有可能彻底改变这种迄今难治性和令人衰弱的疾病的管理。

项目成果

Alopecia areata multiplex following autologous dermal micrograft injection for treatment of androgenetic alopecia

自体真皮微移植注射治疗雄激素性脱发后出现多发性斑秃

• DOI: 10.1111/jdv.15701
• 发表时间: 2019
• 期刊: Journal of the European Academy of Dermatology and Venereology
• 影响因子: 9.2
• 作者: Toshima S.;Kurihara Y.;Wang E.H.C.;Nomura H.;Hayashi Y.;Christiano A.M.;Amagai M.;Umegaki‐Arao N.
• 通讯作者: Umegaki‐Arao N.

Validation of Case Identification for Alopecia Areata Using International Classification of Diseases Coding.

• DOI: 10.4103/ijt.ijt_67_20
• 发表时间: 2020-09
• 期刊: International journal of trichology
• 作者: Lavian J;Li SJ;Lee EY;Bordone LA;Polubriaginof FCG;Christiano AM;Mostaghimi A
• 通讯作者: Mostaghimi A

Authors' reply to: Comment on the article by Dr. Toshima about alopecia areata multiplex following autologous dermal micrograft injection.

作者回复：对Toshima博士关于自体真皮微移植注射后多发性斑秃的文章的评论。

• DOI: 10.1111/jdv.16177
• 发表时间: 2020
• 期刊: Journal of the European Academy of Dermatology and Venereology : JEADV
• 作者: Toshima,S;Kurihara,Y;Wang,EHC;Nomura,H;Hayashi,Y;Christiano,AM;Amagai,M;Umegaki-Arao,N
• 通讯作者: Umegaki-Arao,N